# American Well Corp: financial statements, quarterly

AMWL · NYSE · CIK 1393584 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/amwl.md) · [Financials](/companies/amwl/financials.md) · [Filings](/companies/amwl/filings.md) · [Insiders](/companies/amwl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/amwl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [61.9](/filings/0000950170-24-119005.md) | [70.7 d](/filings/0001193125-26-048776.md) | [59.5](/filings/0000950170-25-061842.md) | [62.8](/filings/0000950170-25-103035.md) | [61.0](/filings/0001193125-25-264718.md) | [71.0 d](/filings/0001193125-26-048776.md) | [66.8](/filings/0001393584-26-000013.md) | [70.9](/filings/0001393584-26-000018.md) | [56.3](/filings/0001193125-25-264718.md) | [55.3 d](/filings/0001193125-26-048776.md) | [54.9](/filings/0001393584-26-000013.md) | [52.0](/filings/0001393584-26-000018.md) |
| Research and development | $m | [27.7](/filings/0000950170-24-119005.md) | [26.3 d](/filings/0001193125-26-048776.md) | [26.7](/filings/0000950170-25-061842.md) | [20.8](/filings/0000950170-25-103035.md) | [19.8](/filings/0001193125-25-264718.md) | [18.8 d](/filings/0001193125-26-048776.md) | [22.1](/filings/0001393584-26-000013.md) | [18.2](/filings/0001393584-26-000018.md) | [18.6](/filings/0001193125-25-264718.md) | [13.9 d](/filings/0001193125-26-048776.md) | [12.4](/filings/0001393584-26-000013.md) | [10.4](/filings/0001393584-26-000018.md) |
| Operating income | $m | [(143)](/filings/0000950170-24-119005.md) | [(57.0) d](/filings/0001193125-26-048776.md) | [(75.0)](/filings/0000950170-25-061842.md) | [(52.4)](/filings/0000950170-25-103035.md) | [(47.4)](/filings/0001193125-25-264718.md) | [(42.8) d](/filings/0001193125-26-048776.md) | [(30.4)](/filings/0001393584-26-000013.md) | [(20.4)](/filings/0001393584-26-000018.md) | [(29.3)](/filings/0001193125-25-264718.md) | [(25.2) d](/filings/0001193125-26-048776.md) | [(17.4)](/filings/0001393584-26-000013.md) | [(9.6)](/filings/0001393584-26-000018.md) |
| Income tax | $m | [1.1](/filings/0000950170-24-119005.md) | [0.5 d](/filings/0001193125-26-048776.md) | [1.3](/filings/0000950170-25-061842.md) | [0.1](/filings/0000950170-25-103035.md) | [(0.1)](/filings/0001193125-25-264718.md) | [1.5 d](/filings/0001193125-26-048776.md) | [0.6](/filings/0001393584-26-000013.md) | [(0.7)](/filings/0001393584-26-000018.md) | [1.2](/filings/0001193125-25-264718.md) | [(0.6) d](/filings/0001193125-26-048776.md) | [0.2](/filings/0001393584-26-000013.md) | [(0.5)](/filings/0001393584-26-000018.md) |
| Net income | $m | [(136)](/filings/0000950170-24-119005.md) | [(48.6) d](/filings/0001193125-26-048776.md) | [(72.1)](/filings/0000950170-25-061842.md) | [(49.9)](/filings/0000950170-25-103035.md) | [(43.5)](/filings/0001193125-25-264718.md) | [(42.7) d](/filings/0001193125-26-048776.md) | [(18.7)](/filings/0001393584-26-000013.md) | [(19.7)](/filings/0001393584-26-000018.md) | [(32.4)](/filings/0001193125-25-264718.md) | [(24.9) d](/filings/0001193125-26-048776.md) | [(10.9)](/filings/0001393584-26-000013.md) | [(9.9)](/filings/0001393584-26-000018.md) |
| Diluted EPS | $ per share | [(9.54)](/filings/0000950170-24-119005.md) | not reported | [(4.94)](/filings/0000950170-25-061842.md) | [(3.36)](/filings/0000950170-25-103035.md) | [(2.87)](/filings/0001193125-25-264718.md) | not reported | [(1.19)](/filings/0001393584-26-000013.md) | [(1.24)](/filings/0001393584-26-000018.md) | [(2.00)](/filings/0001193125-25-264718.md) | not reported | [(0.66)](/filings/0001393584-26-000013.md) | [(0.59)](/filings/0001393584-26-000018.md) |
| Basic EPS | $ per share | [(9.54)](/filings/0000950170-24-119005.md) | not reported | [(4.94)](/filings/0000950170-25-061842.md) | [(3.36)](/filings/0000950170-25-103035.md) | [(2.87)](/filings/0001193125-25-264718.md) | not reported | [(1.19)](/filings/0001393584-26-000013.md) | [(1.24)](/filings/0001393584-26-000018.md) | [(2.00)](/filings/0001193125-25-264718.md) | not reported | [(0.66)](/filings/0001393584-26-000013.md) | [(0.59)](/filings/0001393584-26-000018.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [319](/filings/0000950170-24-119005.md) | [372](/filings/0001193125-26-048776.md) | [309](/filings/0000950170-25-061842.md) | [277](/filings/0000950170-25-103035.md) | [245](/filings/0001193125-25-264718.md) | [228](/filings/0001193125-26-048776.md) | [222](/filings/0001393584-26-000013.md) | [219](/filings/0001393584-26-000018.md) | [201](/filings/0001193125-25-264718.md) | [182](/filings/0001393584-26-000018.md) | [179](/filings/0001393584-26-000013.md) | [196](/filings/0001393584-26-000018.md) |
| Current assets | $m | [489](/filings/0000950170-23-057463.md) | [450](/filings/0000950170-25-019024.md) | [414](/filings/0000950170-24-051315.md) | [378](/filings/0000950170-24-088613.md) | [357](/filings/0000950170-24-119005.md) | [317](/filings/0001193125-26-048776.md) | [312](/filings/0000950170-25-061842.md) | [290](/filings/0000950170-25-103035.md) | [271](/filings/0001193125-25-264718.md) | [247](/filings/0001393584-26-000018.md) | [259](/filings/0001393584-26-000013.md) | [265](/filings/0001393584-26-000018.md) |
| Total assets | $m | [635](/filings/0000950170-23-057463.md) | [590](/filings/0000950170-25-019024.md) | [548](/filings/0000950170-24-051315.md) | [508](/filings/0000950170-24-088613.md) | [483](/filings/0000950170-24-119005.md) | [436](/filings/0001193125-26-048776.md) | [419](/filings/0000950170-25-061842.md) | [389](/filings/0000950170-25-103035.md) | [359](/filings/0001193125-25-264718.md) | [324](/filings/0001393584-26-000018.md) | [326](/filings/0001393584-26-000013.md) | [327](/filings/0001393584-26-000018.md) |
| Current liabilities | $m | [98.7](/filings/0000950170-23-057463.md) | [93.8](/filings/0000950170-25-019024.md) | [108](/filings/0000950170-24-051315.md) | [118](/filings/0000950170-24-088613.md) | [122](/filings/0000950170-24-119005.md) | [111](/filings/0001193125-26-048776.md) | [107](/filings/0000950170-25-061842.md) | [87.9](/filings/0000950170-25-103035.md) | [86.5](/filings/0001193125-25-264718.md) | [73.2](/filings/0001393584-26-000018.md) | [83.8](/filings/0001393584-26-000013.md) | [91.3](/filings/0001393584-26-000018.md) |
| Total liabilities | $m | [115](/filings/0000950170-23-057463.md) | [110](/filings/0000950170-25-019024.md) | [125](/filings/0000950170-24-051315.md) | [130](/filings/0000950170-24-088613.md) | [133](/filings/0000950170-24-119005.md) | [120](/filings/0001193125-26-048776.md) | [114](/filings/0000950170-25-061842.md) | [94.1](/filings/0000950170-25-103035.md) | [92.1](/filings/0001193125-25-264718.md) | [76.0](/filings/0001393584-26-000018.md) | [85.8](/filings/0001393584-26-000013.md) | [92.9](/filings/0001393584-26-000018.md) |
| Shareholders' equity | $m | [502](/filings/0000950170-23-057463.md) | [464](/filings/0000950170-25-019024.md) | [409](/filings/0000950170-24-051315.md) | [364](/filings/0000950170-24-088613.md) | [337](/filings/0000950170-24-119005.md) | [305](/filings/0001193125-26-048776.md) | [294](/filings/0000950170-25-061842.md) | [283](/filings/0000950170-25-103035.md) | [255](/filings/0001193125-25-264718.md) | [236](/filings/0001393584-26-000018.md) | [227](/filings/0001393584-26-000013.md) | [221](/filings/0001393584-26-000018.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(38.0) d](/filings/0000950170-24-119005.md) | [(41.6) d](/filings/0001193125-26-048776.md) | [(59.8)](/filings/0000950170-25-061842.md) | [(21.8) d](/filings/0000950170-25-103035.md) | [(32.4) d](/filings/0001193125-25-264718.md) | [(13.4) d](/filings/0001193125-26-048776.md) | [(25.1)](/filings/0001393584-26-000013.md) | [(4.7) d](/filings/0001393584-26-000018.md) | [(18.8) d](/filings/0001193125-25-264718.md) | [(17.4) d](/filings/0001193125-26-048776.md) | [(1.0)](/filings/0001393584-26-000013.md) | [10.7 d](/filings/0001393584-26-000018.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-119005.md) | [0.1 d](/filings/0001193125-26-048776.md) | [0.1](/filings/0000950170-25-061842.md) | [0.0 d](/filings/0000950170-25-103035.md) | [0.0 d](/filings/0001193125-25-264718.md) | [0.0 d](/filings/0001193125-26-048776.md) | [0.0](/filings/0001393584-26-000013.md) | [0.0 d](/filings/0001393584-26-000018.md) | [0.0 d](/filings/0001193125-25-264718.md) | [0.0 d](/filings/0001193125-26-048776.md) | [0.0](/filings/0001393584-26-000013.md) | [0.0 d](/filings/0001393584-26-000018.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [277](/filings/0000950170-23-057463.md) | [280](/filings/0000950170-24-051315.md) | [14.2](/filings/0000950170-24-088613.md) | [14.3](/filings/0000950170-24-119005.md) | [14.6](/filings/0000950170-25-061842.md) | [14.9](/filings/0000950170-25-103035.md) | [15.1](/filings/0001193125-25-264718.md) | [15.7](/filings/0001393584-26-000013.md) | [15.9](/filings/0001393584-26-000018.md) | [16.2](/filings/0001193125-25-264718.md) | [16.6](/filings/0001393584-26-000013.md) | [16.8](/filings/0001393584-26-000018.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.